Abstract
Prenatal treatment of female fetuses having congenital adrenal hyperplasia (CAH) requires diagnosis of gender for genotype prior to genital differentiation. This approach currently involves chorionic villus sampling (CVS). In experienced hands CVS carries minimal risk of pregnancy loss, comparable to that associated with amniocentesis. Although offering considerable advantage by first trimester diagnosis, CVS is typically performed no earlier than 9-week gestation (7-week embryonic age) and usually not until 10–12 weeks. The procedure can be performed as early as 6–7 weeks, but it is technically difficult at that gestational age and associated with limb reduction defects. A preferable approach is definitive non-invasive diagnosis of fetal disorders. This could be achievable by analysis of either intact fetal cells or cell-free fetal DNA in maternal blood.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this paper
Cite this paper
Simpson, J.L., Bischoff, F. (2011). Novel Non-invasive Prenatal Diagnosis as Related to Congenital Adrenal Hyperplasia. In: New, M., Simpson, J. (eds) Hormonal and Genetic Basis of Sexual Differentiation Disorders and Hot Topics in Endocrinology: Proceedings of the 2nd World Conference. Advances in Experimental Medicine and Biology, vol 707. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-8002-1_8
Download citation
DOI: https://doi.org/10.1007/978-1-4419-8002-1_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-8001-4
Online ISBN: 978-1-4419-8002-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)